Michael Choi, MD, discusses the long-term efficacy of ibrutinib given as a frontline treatment in chronic lymphocytic leukemia.
Michael Choi, MD, UC San Diego Medical Center
Advertisement
Articles by Michael Choi, MD, UC San Diego Medical Center
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
2
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
3
Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC
4
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
5